ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q2 2024 ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Why Is Cancer Vaccine Developer Elicio Therapeutics Stock Trading Lower On Friday? Elicio Therapeutics announced promising preliminary data from the AMPLIFY-7P Phase 1a study of ELI-002 7P, showing extended median disease-free survival in patients with mKRAS-driven solid tumors.
Why Is Elicio Therapeutics (ELTX) Stock Down 36% Today? Elicio Therapeutics stock is down on Friday after the company announced a proposed public offering for shares of ELTX this morning.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday Pre-market stock movers are a hot topic on Friday and we're breaking down all of the latest news sending shares higher and lower!
Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors Elicio Therapeutics Unveils Promising Phase 1a Data For ELI-002 7P In mKRAS Tumors
ELTX Stock Earnings: Elicio Therapeutics Beats EPS for Q1 2024 ELTX stock results show that Elicio Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.
